HEXIM1-Tat chimera inhibits HIV-1 replication

Area of Science:

• Molecular Biology
• Virology
• Drug Discovery

Background:

• HIV transcription is essential for viral replication, relying on the cellular positive transcription elongation factor b (P-TEFb).
• The viral Tat protein recruits P-TEFb to the HIV promoter (TAR) to drive transcription, overcoming inhibition by HEXIM1 bound to the 7SK small nuclear ribonucleoprotein.
• Targeting HIV transcription is a critical strategy for developing antiviral therapies.

Purpose of the Study:

• To design and evaluate a novel chimeric inhibitor (HT1) of HIV transcription.
• To investigate HT1's mechanism of action, targeting the interaction between Tat, P-TEFb, and the HIV promoter.
• To assess HT1's efficacy in inhibiting HIV replication and reactivation in cellular models.

Main Methods:

• Design of a chimeric peptide (HT1) combining functional domains of HEXIM1 and Tat.
• In vitro assessment of HT1's inhibition of HIV gene expression from the HIV promoter.
• Evaluation of HT1's ability to compete with Tat for binding to TAR and P-TEFb.
• Testing HT1's efficacy in inhibiting spreading HIV infection and viral reactivation in T cell line models of HIV latency.

Main Results:

• The chimera HT1 potently inhibited gene expression from the HIV promoter.
• HT1 competed with Tat for binding to TAR and P-TEFb, maintaining P-TEFb inactivation.
• HT1 effectively inhibited spreading HIV infection and viral reactivation in cellular models.
• HT1 demonstrated minimal impact on cellular transcription and metabolism.

Conclusions:

• The chimeric inhibitor HT1 represents a novel and effective strategy for blocking HIV transcription.
• Peptide mimicry and competition for RNA-protein interactions offer a viable approach for HIV therapeutic development.
• HT1 shows potential as a new candidate for HIV therapy or as part of a "block and lock" strategy for HIV cure.